Novamab leverages an unparalleled single-domain antibody (sdAb) and unmet clinical needs oriented strategy to establish multiple innovative platforms while incubating competitively positioned first-in-class drugs since founded in 2017. With a robust R&D foundation over 6 years, Novamab has upgraded multiple platforms, including inhaled sdAb, synthetic cytokine surrogate, etc. These advancements encompass more than 10 drug candidates across various therapeutic areas, respiratory diseases, autoimmune diseases, ophthalmology, and oncology. Our flagship drug candidate, LQ036, the FIC inhaled sdAb neutralizing IL-4Rα for asthma and COPD treatment, is currently progressing phase 2 clinical development. Another promising candidate, LQ043H, the first inhaled sdAb neutralizing TSLP for asthma and COPD treatment, is slated to advance into phase 2 trials in 2024. Novamab is actively developing innovative drugs, while simultaneously seeking collaboration and commercial partnerships.